The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Stable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors
Open accessAbstract
Human immunodeficiency virus (HIV)-based lentiviral vectors (LVs) hold immense promise for gene delivery applications because of their relatively large packaging capacity and their ability to infect a range of cell types. The genome of HIV non-specifically integrates into the host genome, and this promotes efficient, stable transgene expression in dividing cells. However, integration can also be problematic because of variations in gene expression among cells, possible gene silencing and, most importantly, insertional mutagenesis which can lead to undesirable effects such as malignant transformation. In order to alleviate these problems, we have developed a range of non-integrating LVs (NILVs) by introducing point mutations into the catalytic site, chromosome binding site, and viral DNA binding site of the viral integrase (IN). In addition, we have mutated the IN attachment (att) sites within the HIV long terminal repeats (LTRs). All of the vectors produced show efficient reverse transcription and transgene expression in dividing cells and prolonged expression in non-dividing myotubes. Finally, we show that NILV can be used for achieving highly effective gene transfer and expression in muscle in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Any alterations to these amino acids will inactivate the catalytic activity of IN and inhibit the integration while preserving the transgene expression [20,29,30].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [20]
In the citing paper
“A non-integrating LV was engineered to avoid unwanted integration. In these vectors, selected mutations were induced within the integrase coding region to eliminate the integrase activities without affecting reverse transcription and transport of the pre-integrating complex into the nucleus [48,49,50].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [50]
Citations
Cites
A simple salting out procedure for extracting DNA from human nucleated cells
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.1215 · Cited by 20,330
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., & Yee, J. K. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8033 · Cited by 1,399
A quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S. T., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 687 · cited 1×
“(a) Integrase domains: bold font represents conserved amino acids [Zinc (Zn) finger (HHCC) and catalytic core (DD(35)E], mutated residues are underlined.”
BackgroundDemaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M., & Thrasher, A. J. (2002) · Human Gene Therapy · doi:10.1089/10430340252898984 · Cited by 486
Self-citationGallay, P., Hope, T., Chin, D., & Trono, D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9825 · Cited by 485
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460
Self-citationBrown, P. O., Bowerman, B., Varmus, H. E., & Bishop, J. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2525 · Cited by 399
Cited by
MicroRNA: Biogenesis, Function and Role in Cancer
MacFarlane, L.-A., & R. Murphy, P. (2010) · Current Genomics · doi:10.2174/138920210793175895 · Cited by 1,584
“Viral vectors are being modified to improve expression specificity and make them safer for human trials [374, 381].”
BackgroundSchaller, T., Ocwieja, K. E., Rasaiyaah, J., Price, A. J., Brady, T. L., Roth, S. L., Hué, S., Fletcher, A. J., Lee, K., KewalRamani, V. N., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002439 · Cited by 470
“Total DNA was purified from 2 samples at each time point (QiaAmp, Qiagen) and 600 ng were subjected to Taqman quantitative PCR using late RT [55], 2-LTR circle [56] or GFP [53] primers and probe to detect provirus as described.”
MethodLentiviral vectors: basic to translational
Sakuma, T., Barry, M. A., & Ikeda, Y. (2012) · Biochemical Journal · doi:10.1042/bj20120146 · Cited by 336
Recent Advances in Lentiviral Vector Development and Applications
Mátrai, J., Chuah, M. K., & VandenDriessche, T. (2010) · Molecular Therapy · doi:10.1038/mt.2009.319 · Cited by 347
Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential
Escors, D., & Breckpot, K. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0063-4 · Cited by 344
“Then, the lentivector DNA remains in the nucleus as an episome, leading to sustained expression in post-mitotic cells and tissues such as retina, brain, and muscle (Apolonia et al. 2007; Philippe et al. 2006; Yanez-Munoz et al. 2006).”
Kaufmann, K. B., Büning, H., Galy, A., Schambach, A., & Grez, M. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202287 · Cited by 276
“…IDLV could be very useful in settings where only transient transgene expression is required, as for instance in vaccination approaches or for the delivery of transposases or designer nucleases, which are discussed later in this review (Apolonia et al, 2007; Hu et al, 2010; Lombardo et al, 2007).”
Viral vectors for gene delivery to the central nervous system
Lentz, T. B., Gray, S. J., & Samulski, R. J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.014 · Cited by 271
Viral Delivery Systems for CRISPR
Xu, C. L., Ruan, M. Z. C., Mahajan, V. B., & Tsang, S. H. (2019) · Viruses · doi:10.3390/v11010028 · Cited by 277
Integration-deficient Lentiviral Vectors: A Slow Coming of Age
Wanisch, K., & Yáñez-Muñoz, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.122 · Cited by 222
Ortinski, P. I., O’Donovan, B., Dong, X., & Kantor, B. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.002 · Cited by 146
“Several studies have demonstrated broadly similar levels of illegitimate integration.(27,34,35)”
BackgroundMátrai, J., Cantore, A., Bartholomae, C. C., Annoni, A., Wang, W., Acosta-Sanchez, A., Samara-Kuko, E., De Waele, L., Ma, L., Genovese, P., et al. (2011) · Hepatology · doi:10.1002/hep.24230 · Cited by 139
“In contrast, IDLVs have been reported to support sustained transgene expression in quiescent mouse tissues, such as the retina and central nervous system, likely because the episomal vector DNA is retained within the postmitotic nucleus.(17,18,20) Despite these advances, the ability of IDLVs to achieve therapeutically…”
BackgroundHIV-1 Lentiviral Vector Immunogenicity Is Mediated by Toll-Like Receptor 3 (TLR3) and TLR7
Breckpot, K., Escors, D., Vargas, F. A., Lopes, L., Karwacz, K., Lint, S. V., Keyaerts, M., & Collins, M. K. (2010) · Journal of Virology · doi:10.1128/jvi.00014-10 · Cited by 139
“characterized as previously described (2, 7).”
Self-citationThe TRIM Family Protein KAP1 Inhibits HIV-1 Integration
Allouch, A., Primio, C. D., Alpi, E., Lušić, M., Arosio, D., Giacca, M., & Cereseto, A. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.05.004 · Cited by 145
“The role of this modification during the viral life cycle is proven by the decreased infectivity and provirus formation following inhibition of IN acetylation (Apolonia et al., 2007; Cereseto et al., 2005; Terreni et al., 2010; Topper et al., 2007).”
BackgroundIntegrase-defective lentiviral vectors: Progress and applications
Banasik, M. B., & McCray, P. B. (2010) · Gene Therapy · doi:10.1038/gt.2009.135 · Cited by 129
New developments in lentiviral vector design, production and purification
Segura, M. M., Mangion, M., Gaillet, B., & Garnier, A. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.779249 · Cited by 133
“The LVV DNA thus remains in the cell nucleus as an episome, leading to sustained expression in post-mitotic cells and tissues such as the retina [69], brain [69,70] and muscle [71].”
BackgroundGutiérrez-Guerrero, A., Cosset, F., & Verhoeyen, E. (2020) · Viruses · doi:10.3390/v12091016 · Cited by 128
“These non-integrative LVs have been used efficiently in post-mitotic tissues, especially in combination with gene editing tools (zinc finger nucleases (ZFN), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9); see p…”
MethodViral complementation allows HIV-1 replication without integration
Gelderblom, H. C., Vatakis, D. N., Burke, S. A., Lawrie, S. D., Bristol, G. C., & Levy, D. N. (2008) · Retrovirology · doi:10.1186/1742-4690-5-60 · Cited by 131
“It might be useful to exploit such an interfering mechanism to therapeutically intervene in HIV-1 infection [78] with non-integrating lentiviral vectors [79,80].”
BackgroundNovel targeted therapies for Parkinson’s disease
Ntetsika, T., Papathoma, P.-E., & Markaki, I. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00279-2 · Cited by 131
“lentivectors and, more recently, removal of a sequence element involved in plus-strand DNA synthesis shown to further reduce integration and increase the efficiency of formation of circular episomes (Apolonia et al. 2007; Gijsbers et al. 2010; Kantor et al. 2011; Philippe et al. 2006; Zufferey et al. 1998).”
BackgroundDelivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9
LaFountaine, J. S., Fathe, K., & Smyth, H. D. C. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.029 · Cited by 111
Baruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 114
“…integration-deficient lentiviral vectors (Nightingale et al 2006; Philippe et al 2006; Yanez-Munoz et al 2006), which have shown long-lasting gene expression in non-dividing tissues (Apolonia et al 2007; Rahim et al 2009) and phenotype correction in mice with haemophilia B (Suwanmanee et al 2014).”
BackgroundSelf-citationOcular gene delivery using lentiviral vectors
Balaggan, K. S., & Ali, R. R. (2011) · Gene Therapy · doi:10.1038/gt.2011.153 · Cited by 108
State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Pauwels, K., Gijsbers, R., Toelen, J., Schambach, A., Willard-Gallo, K., Verheust, C., Debyser, Z., & Herman, P. (2009) · Current Gene Therapy · doi:10.2174/156652309790031120 · Cited by 106
“Taking advantage of these episomal circles, IDLV have recently emerged as novel and efficient gene carriers, facilitating high levels of transient expression from linear and circular DNA forms [85-88].”
BackgroundMashel, T. V., Tarakanchikova, Y. V., Muslimov, A. R., Zyuzin, M. V., Timin, A. S., Lepik, K. V., & Fehse, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120282 · Cited by 105
In Vivo Delivery Systems for Therapeutic Genome Editing
Wang, L., Li, F., Dang, L., Liang, C., Wang, C., He, B., Liu, J., Li, D., Wu, X., Xu, X., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050626 · Cited by 108
“For example, the transduction efficiency of hepatocytes in mice with IDLVs is less than integrating LVs, while IDLVs can achieve highly-effective gene transfer and expression in mice muscle in vivo [37,39].”
BackgroundHybrid Lentivirus-transposon Vectors with a Random Integration Profile in Human Cells
Staunstrup, N. H., Moldt, B., Mátés, L., Villesen, P., Jakobsen, M., Ivics, Z., Izsvák, Z., & Mikkelsen, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.10 · Cited by 96
A Large U3 Deletion Causes Increased In Vivo Expression from a Nonintegrating Lentiviral Vector
Bayer, M., Kantor, B., Cockrell, A., Ma, H., Zeithaml, B., Li, X., McCown, T., & Kafri, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.199 · Cited by 94
“Several groups recently demonstrated notable in vitro and in vivo expression from nonintegrating, self-inactivating (SIN) lentiviral vectors [17,18,28,30,34].”
BackgroundResultImmunization delivered by lentiviral vectors for cancer and infectious diseases
Hu, B., Tai, A., & Wang, P. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00967.x · Cited by 93
Karwacz, K., Mukherjee, S., Apolonia, L., Blundell, M. P., Bouma, G., Escors, D., Collins, M. K., & Thrasher, A. J. (2009) · Journal of Virology · doi:10.1128/jvi.02519-08 · Cited by 87
“A low level of residual background integration has been reported to occur in spite of an integrase-deficient gag-pol packaging construct being employed (1).”
BackgroundMethodSelf-citationEngineered cell entry links receptor biology with single-cell genomics
Yu, B., Shi, Q., Belk, J. A., Yost, K. E., Parker, K. R., Li, R., Liu, B. B., Huang, H., Lingwood, D., Greenleaf, W. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.11.016 · Cited by 91
Xie, R., Cheng, M., Li, M., Xiong, X., Daadi, M. M., Sapolsky, R. M., & Zhao, H. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.132 · Cited by 86
Moldt, B., Miskey, C., Staunstrup, N. H., Gogol‐Döring, A., Bak, R. O., Sharma, N., Mátés, L., Izsvák, Z., Chen, W., Ivics, Z., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.47 · Cited by 90
PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways
Xiong, X., Xie, R., Zhang, H., Gu, L., Xie, W., Cheng, M., Jian, Z., Kovacina, K. S., & Zhao, H. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.02.006 · Cited by 83
GCN5-dependent acetylation of HIV-1 integrase enhances viral integration
Terreni, M., Valentini, P., Liverani, V., Gutiérrez, M. I., Primio, C. D., Fenza, A. D., Tozzini, V., Allouch, A., Albanese, A., Giacca, M., et al. (2010) · Retrovirology · doi:10.1186/1742-4690-7-18 · Cited by 85
“Moreover, by using a genetic assay where integration was evaluated through the number of cell clones containing proviruses, one report [2] detailed almost half decreased integration efficiency, while the other [37] indicated a 14-fold lower residual integration rate.”
BackgroundMethodNon-Integrating Lentiviral Vectors
Sarkis, C., Philippe, S., Mallet, J. J., & Serguera, C. (2008) · Current Gene Therapy · doi:10.2174/156652308786848012 · Cited by 83
“NIL vectors with a clearly non-integrating phenotype can be obtained by introducing mutations into any of these regions [71-73, 84] (Table 1).”
BackgroundInfluentialSleeping Beauty Transposition From Nonintegrating Lentivirus
Vink, C. A., Gaspar, H. B., Gabriel, R., Schmidt, M., McIvor, R. S., Thrasher, A. J., & Qasim, W. (2009) · Molecular Therapy · doi:10.1038/mt.2009.94 · Cited by 78
Self-citationUse of HIV as a gene transfer vector.
Pluta, K. D., & Kacprzak, M. M. (2009) · Acta Biochimica Polonica · doi:10.18388/abp.2009_2490 · Cited by 89
“, 2009) and to muscle in vivo (Apolonia et al., 2007) as well as in the transposase-directed genomic integration of the minimal gene expression cassette (Vink et al.”
BackgroundGenetic engineering of stem cells for enhanced therapy
Nowakowski, A., Andrzejewska, A., Janowski, M., Walczak, P., & Łukomska, B. (2013) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2013-1918 · Cited by 79
“The integration of lentiviruses, similar to retroviruses, is random; however, it has been shown that, with targeted mutations of the integrase gene, it was possible to achieve episomal forms of the vector without the risk of a non-specific integration of the transgene (Apolonia et al. 2007).”
BackgroundProtease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells
Titanji, B. K., Aasa-Chapman, M. M. I., Pillay, D., & Jolly, C. L. (2013) · Retrovirology · doi:10.1186/1742-4690-10-161 · Cited by 78
“The primers used were 5′-AACT AGAGATCCCT CAGACCCTTTT-3′ and 5′-CTTGTCTTCGTTGGGA GTGAATT-3′, and Taqman probe 5′-CTAGAGATTTT CCACACTGAC-3′ [53].”
In Vivo Cellular Imaging for Translational Medical Research
Arbab, A. S., Janic, B., Haller, J., Pawelczyk, E., Liu, W. X., & Frank, J. A. (2009) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/157340509787354697 · Cited by 78
“Currently, lentiviral and non-integrating lentiviral vector [36] based transduction has become increasingly popular owing to its highly efficient, long-term incorporation, with efficacy now extending to include stem cells [37, 38].”
BackgroundProtective Antiviral Immunity Conferred by a Nonintegrative Lentiviral Vector-Based Vaccine
Coutant, F., Frenkiel, M.-P., Despres, P., & Charneau, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003973 · Cited by 70
“undetectable levels, as previously described [20,21], confirming the non integrated status of the vector genome (data not shown).”
BackgroundResultNon-viral gene therapy for neurological diseases, with an emphasis on targeted gene delivery
Rogers, M., & Rush, R. A. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.026 · Cited by 77
“ficiency disease were rendered functional by stem cell gene therapy in human trials using a retrovirus vector, but unfortunately, five children developed a leukemia-type disease and one died owing to insertional mutagenesis [2–5].”
BackgroundMethodNon-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through
Gurumoorthy, N., Nordin, F., Tye, G. J., Wan Kamarul Zaman, W. S., & Ng, M. H. (2022) · Biomedicines · doi:10.3390/biomedicines10010107 · Cited by 69
Jin, C., Fotaki, G., Ramachandran, M., Nilsson, B., Essand, M., & Yu, D. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505869 · Cited by 66
“74DNW (Apolonia et al, 2007), which has three class I point mutations in the integrase coding sequence thus abolished the integration activity.”
BackgroundDelivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
“Some studies show that NILs have reduced efficiency [139], with 2–10 fold lower expression in vitro compared to conventional LVs, yet separate studies show that NIL and conventional LV vectors have equivalent transduction efficiencies in vivo [137].”
Design and potential of non-integrating lentiviral vectors
Shaw, A., & Cornetta, K. (2014) · Biomedicines · doi:10.3390/biomedicines2010014 · Cited by 60
“Injections of integrase deficient LV and att site mutant NILV into mouse muscle were found to provide levels of transgene expression similar to wild-type LV for up three months post-transduction [61].”
BackgroundMethodInfluentialLDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives
Al-Allaf, F. A., Coutelle, C., Waddington, S. N., David, A. L., Harbottle, R. P., & Themis, M. (2010) · International Archives of Medicine · doi:10.1186/1755-7682-3-36 · Cited by 70
“Recent studies using IDLVs have demonstrated effective gene transfer in the eye [176], brain [174,179], muscle [180], and to a lesser extent in the liver [181], albeit at lower expression levels than with integrating vectors.”
BackgroundSelf-citationPelascini, L. P. L., Janssen, J. M., & Gonçalves, M. A. F. V. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.069 · Cited by 64
“, 2006), skeletal muscle (Apolonia et al., 2007), and the liver (Mátrai et al.”
BackgroundThe old and the new: Prospects for non-integrating lentiviral vector technology
Apolonia, L. (2020) · Viruses · doi:10.3390/v12101103 · Cited by 58
“However, the combination of mutations in the viral DNA and in the viral integrase can reduce illegitimate or background integration but does not act synergistically to lower integration much further [40,43].”
BackgroundSelf-citationTowards the Clinical Application of Gene Therapy for Genetic Inner Ear Diseases
Lahlou, G., Calvet, C., Giorgi, M., Lecomte, M.-J., & Safieddine, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031046 · Cited by 57
Kantor, B., Bayer, M., Ma, H., Samulski, J., Li, C., McCown, T., & Kafri, T. (2011) · Molecular Therapy · doi:10.1038/mt.2010.277 · Cited by 56
Retroviral and Lentiviral Vectors for the Induction of Immunological Tolerance
Dufait, I., Liechtenstein, T., Lanna, A., Bricogne, C., Laranga, R., Padella, A., Breckpot, K., & Escors, D. (2012) · Scientifica · doi:10.6064/2012/694137 · Cited by 65
“ese lentivectors can be generated straightforwardly by introducing inactivating mutations in the integrase coding region, or integrase-binding sites in the transfer vector [118, 135].”
Mlčochová, P., Caswell, S. J., Taylor, I. A., Towers, G. J., & Gupta, R. K. (2017) · The EMBO Journal · doi:10.15252/embj.201796880 · Cited by 55
“2-LTR circles were quantified in triplicate by qPCR as described (Apolonia et al, 2007).”
MethodAn HIV-1 Replication Pathway Utilizing Reverse Transcription Products That Fail To Integrate
Trinité, B., Ohlson, E. C., Voznesensky, I., Rana, S. P., Chan, C. N., Mahajan, S., Alster, J., Burke, S. A., Wodarz, D., & Levy, D. N. (2013) · Journal of Virology · doi:10.1128/jvi.01939-13 · Cited by 59
Development and use of SIV-based Integrase defective lentiviral vector for immunization
Michelini, Z., Negri, D. R. M., Baroncelli, S., Spada, M., Leone, P., Bona, R., Klotman, M. E., & Cara, A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.070 · Cited by 47
Romano, G. (2012) · ISRN Oncology · doi:10.5402/2012/616310 · Cited by 55
“Studies on mouse models focused on in vivo gene delivery of episomal lentiviral vectors in the central nervous system [128], stem cells of the hematopoietic compartment [130], muscles [131], and ocular tissues [135].”
BackgroundEfficient gene targeting mediated by a lentiviral vector-associated meganuclease
Izmiryan, A., Basmaciogullari, S., Henry, A., Pâques, F., & Danos, O. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr524 · Cited by 46
Bulli, L., Apolonia, L., Kutzner, J., Pollpeter, D., Goujon, C., Herold, N., Schwarz, S.-M., Giernat, Y., Keppler, O. T., Malim, M. H., et al. (2016) · Journal of Virology · doi:10.1128/jvi.00458-16 · Cited by 53
“TaqMan quantitative PCR (qPCR) was performed using the GFP primers CAACAGCCACAACGTCTATATCAT/A TGTTGTGGCGGATCTTGAAG (forward/reverse) and the probe FAMCCGACAAGCAGAAGAACGGCATCAA-TAMRA (where FAM is 6- carboxyfluorescein and TAMRA is 6-carboxytetramethylrhodamine) and the 2-long terminal repeat (2-LTR) circle primers AAC…”
Self-citationHu, B., Dai, B., & Wang, P. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.012 · Cited by 45
“To date, several reports have firmly established the utility of IDLVs for mediating gene delivery with high efficacy to a range of post-mitotic tissues [20-23] and for inducing antigen-specific immune responses upon in vivo immunization [24-27].”
BackgroundResultGuan, J., Zhang, J., Zhu, Z., Niu, X., Guo, S., Wang, Y., & Zhang, C. (2015) · Stem Cell Research & Therapy · doi:10.1186/scrt539 · Cited by 45
“Lentiviral vectors facilitate long-term target gene expression and are attractive with regard to gene therapy [24].”
BackgroundGenomic insertion of lentiviral DNA circles directed by the yeast Flp recombinase
Moldt, B., Staunstrup, N. H., Jakobsen, M., Yáñez-Muñoz, R. J., & Mikkelsen, J. G. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-60 · Cited by 44
“However, integration-defective lentiviral (IDLV) vectors carrying an inactive integrase protein that abolish the normal viral integration pathway have recently emerged as novel efficient gene carriers, facilitating high levels of transient expression from linear and circular DNA forms [6-9].”
BackgroundDevelopment of Viral Vectors for Use in Cardiovascular Gene Therapy
Williams, P. D., Ranjzad, P., Kakar, S. J., & Kingston, P. A. (2010) · Viruses · doi:10.3390/v2020334 · Cited by 51
“Sustained transgene expression with non-integrating lentivirus has been demonstrated in vivo in the rodent brain [115], retina [116], skeletal muscle [117] and liver [118].”
BackgroundVink, C. A., Counsell, J. R., Perocheau, D. P. B., Karda, R., Buckley, S. M. K., Brugman, M. H., Galla, M., Schambach, A., McKay, T. R., Waddington, S. N., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.028 · Cited by 43
Self-citationMechanisms controlling titer and expression of bidirectional lentiviral and gammaretroviral vectors
Maetzig, T., Galla, M., Brugman, M. H., Loew, R., Baum, C., & Schambach, A. (2009) · Gene Therapy · doi:10.1038/gt.2009.129 · Cited by 45
Kumar, P., & Chan, W. (2011) · Current Gene Therapy · doi:10.2174/156652311794940782 · Cited by 44
“A variety of integration-deficient LVs (IDLVs) were developed by introducing point mutations into the binding/catalytic site at the viral DNA and the chromosome binding site [85-87].”
Desmin-regulated Lentiviral Vectors for Skeletal Muscle Gene Transfer
Talbot, G., Waddington, S. N., Bales, O., Tchen, R. C., & Antoniou, M. N. (2009) · Molecular Therapy · doi:10.1038/mt.2009.267 · Cited by 41
Self-citationLentiviral Vectors for Anti-Tumor Immunotherapy
Breckpot, K., Emeagi, P. U., & Thielemans, K. (2008) · Current Gene Therapy · doi:10.2174/156652308786848058 · Cited by 41
Efficient gene expression from integration-deficient lentiviral vectors in the spinal cord
Peluffo, H., Foster, E., Ahmed, S. G., Lago, N., Hutson, T. H., Moon, L., Yip, P., Wanisch, K., Caraballo-Miralles, V, Olmos, G., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.78 · Cited by 40
Recent Gene Therapy Advancements for Neurological Diseases
The University of North Carolina at Chapel Hill University Libraries (2013) · PubMed · doi:10.17615/ze6f-8f23 · Cited by 47
Vascular Smooth-Muscle-Cell Activation
Cecchettini, A., Rocchiccioli, S., Boccardi, C., & Citti, L. (2011) · International review of cytology · doi:10.1016/b978-0-12-386041-5.00002-9 · Cited by 51
“A new generation of lentiviral vectors displaying reduced risks of both active virus recombination and oncogenesis is under development (Apolonia et al., 2007; Bayer et al., 2008).”
BackgroundAlbershardt, T. C., Campbell, D. J., Parsons, A. J., Slough, M. M., ter Meulen, J., & Berglund, P. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.10 · Cited by 38
Verghese, S. C., Goloviznina, N. A., Skinner, A. M., Lipps, H. J., & Kurre, P. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku082 · Cited by 38
“Although background integration by niLV vectors, packaged with the integrase mutant D64V, can occur as a result of cellular recombination, no such events were obvious in the clones analyzed (8,38,39).”
BackgroundInterface Oral Health Science 2016
Takahashi, N., Sasaki, K., & Suzuki, O. (2016) · Springer eBooks · doi:10.1007/978-981-10-1560-1 · Cited by 36
Nielsen, T. T., Jakobsson, J., Rosenqvist, N., & Lundberg, C. (2009) · BMC Biotechnology · doi:10.1186/1472-6750-9-13 · Cited by 36
“However, several recent reports demonstrate efficient transgene expression from non-integrating lentiviral vectors present as classical 1-LTR or 2LTR circles[34,35].”
BackgroundMeng, J., Counsell, J. R., Reza, M., Laval, S. H., Danos, O., Thrasher, A. J., Lochmüller, H., Muntoni, F., & Morgan, J. E. (2016) · Scientific Reports · doi:10.1038/srep19750 · Cited by 36
Self-citationUse of lentiviral vectors in vaccination
Ku, M., Charneau, P., & Majlessi, L. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1988854 · Cited by 38
“cell division, as shown in muscles and DCs [53,54].”
BackgroundNegri, D. R. M., Blasi, M., LaBranche, C. C., Parks, R., Balachandran, H., Lifton, M. A., Shen, X., Denny, T. N., Ferrari, G., Vescio, M. F., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.123 · Cited by 35
Current Non-Viral-Based Strategies to Manufacture CAR-T Cells
Gehrke, L., Gonçalves, V. D. R., Andrae, D., Raskó, T., Ho, P., Einsele, H., Hudecek, M., & Friedel, S. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413685 · Cited by 36
“Continuous, systematic refinement of DNA vector composition has allowed for the development of non-integrating lentiviral-derived vectors (NILV) [122] capable of nuclear extra-chromosomal replication.”
Chick, H. E., Nowrouzi, A., Fronza, R., McDonald, R. A., Kane, N. M., Alba, R., Delles, C., Sessa, W. C., Schmidt, M., Thrasher, A. J., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.042 · Cited by 35
“…organs (eye, muscle, central nervous system, and liver of rodents), by retaining transduction efficiency of their wild-type integrase versions with minimal host genome integration in vitro and in vivo (Yanez-Munoz et al., 2006; Apolonia et al., 2007; Rahim et al., 2009; Matrai et al., 2011).”
InfluentialSelf-citationTareen, S. U., Kelley-Clarke, B., Nicolai, C. J., Cassiano, L., Nelson, L. T., Slough, M. M., Vin, C. D., Odegard, J., Sloan, D. D., Hoeven, N. V., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.278 · Cited by 32
Reuschl, A., Mesner, D., Shivkumar, M., Whelan, M. V. X., Pallett, L. J., Guerra‐Assunção, J. A., Madansein, R., Dullabh, K. J., Sigal, A., Thornhill, J. P., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110650 · Cited by 36
Development of gene therapy for treatment of age‐related macular degeneration
Askou, A. L. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12452 · Cited by 35
“Even though most reports note similar vector titers and transduction percentages as integration-competent LVs (ICLVs), the expression level from IDLVs is reduced from approximately one-half (Apolonia et al. 2007; Coutant et al. 2008) to one-tenth of ICLVs (Cornu & Cathomen 2007; Bayer et al. 2008).”
BackgroundIntegrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity
Negri, D. R. M., Michelini, Z., Bona, R., Blasi, M., Filati, P., Leone, P., Rossi, A., Franco, M., & Cara, A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.571670 · Cited by 32
“Importantly, recent reports have shown that in vivo-delivered IDLV persist in a model animal for up to one year from the inoculum in non dividing cells or tissues [43-48].”
BackgroundGene Delivery of a Mutant TGFβ3 Reduces Markers of Scar Tissue Formation After Cutaneous Wounding
Waddington, S. N., Crossley, R., Sheard, V., Howe, S. J., Buckley, S. M. K., Coughlan, L., Gilham, D. E., Hawkins, R. E., & McKay, T. R. (2010) · Molecular Therapy · doi:10.1038/mt.2010.174 · Cited by 34
Self-citationKwilas, A. R., Yednak, M. A., Zhang, L., Liesman, R. M., Collins, P. L., Pickles, R. J., & Peeples, M. E. (2010) · Journal of Virology · doi:10.1128/jvi.00346-10 · Cited by 30
“The pseudotyping of lentiviruses and the creation of nonintegrating lentiviruses may also make them a more suitable vector for targeting the airway (3, 5, 12, 46, 70, 72, 86).”
BackgroundLin, Y.-Y., Belle, I., Blasi, M., Huang, M.-N., Buckley, A. F., Rountree, W., Klotman, M. E., Cara, A., & Negri, D. R. M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.008 · Cited by 28
Blasi, M., Negri, D. R. M., LaBranche, C. C., Alam, S. M., Baker, E. J., Brunner, E. C., Gladden, M. A., Michelini, Z., Vandergrift, N., Wiehe, K. J., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0131-6 · Cited by 27
Targeted DNA Demethylation: Vectors, Effectors and Perspectives
Yano, N., & Fedulov, A. V. (2023) · Biomedicines · doi:10.3390/biomedicines11051334 · Cited by 29
Schaller, T., Bulli, L., Pollpeter, D., Betancor, G., Kutzner, J., Apolonia, L., Herold, N., Burk, R., & Malim, M. H. (2017) · Journal of Virology · doi:10.1128/jvi.00463-17 · Cited by 27
“TaqMan qPCR was performed using GFP forward/reverse primers 5=-CAA CAG CCA CAA CGT CTA TAT CAT-3=/5=-ATG TTG TGG CGG ATC TTG AAG-3= and the probe 6-carboxyfluorescein (FAM)–5=–CCG ACA AGC AGA AGA ACG GCA TCA A–3=–5-carboxytetramethylrhodamine (TAMRA), and for 2-LTR circle primers 5=-AAC TAG AGA TCC CTC AGA CCG AAA A-3…”
BackgroundSelf-citationHu, B., Yang, H., Dai, B., Tai, A., & Wang, P. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.012 · Cited by 26
“The resulting NILVs could retain their ability to effectively transduce dividing and nondividing cells while providing long-term transgene expression in a variety of postmitotic tissues (Philippe et al., 2006; YanezMunoz et al., 2006; Apolonia et al., 2007).”
InfluentialJi, H., Lu, P., Liu, B., Qu, X., Wang, Y., Jiang, Z., Yang, X., Zhong, Y., Yang, H. B., Pan, H., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.04.014 · Cited by 26
“Integrase-deficient lentiviral titers are relatively low.(25,26) Conclusively, the application of an adenovirus vector delivering the inducible ZFNs is much better.”
BackgroundShchemelev, A. N., Davydenko, V. S., Ostankova, Y. V., Reingardt, D. E., Николаевна, С. Е., Zueva, E. B., & Тотолян, А. А. (2024) · Viruses · doi:10.3390/v16111682 · Cited by 25
Gene delivery in tissue engineering and regenerative medicine
Fang, Y. L., Chen, X., & Godbey, W. T. (2014) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.33354 · Cited by 25
Pleiotropic Nature of HIV‐1 Integrase Mutations
Engelman, A. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch6 · Cited by 24
Lu‐Nguyen, N., Broadstock, M., Schliesser, M. G., Bartholomae, C. C., Kalle, C. V., Schmidt, M., & Yáñez‐Muñoz, R. J. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.003 · Cited by 25
“…experiments using IDLVs have focused on a relatively short time scale (weeks), with very few studies so far confirming efficient and long-lasting CNS gene expression in vivo (Phi-lippe et al ., 2006; Ya´n˜ez-Mun˜oz et al ., 2006; Apolonia et al ., 2007; Rahim et al ., 2009; Hutson et al ., 2012).”
Li, X., Gu, S., Ling, Y., Shen, C., Cao, X., & Xie, R. (2015) · Brain Research · doi:10.1016/j.brainres.2015.02.009 · Cited by 23
Recent Advances in Lentiviral Vaccines for HIV-1 Infection
Norton, T. D., & Miller, E. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00243 · Cited by 23
“Despite the weaker potency that has been observed when compared with integrative LV vectors, IDLV have been effective in stable transduction following IM administration in mice (74, 75) and has proven effective in multiple models of infection, including West Nile virus (76), HPV-associated tumors (77), and malaria (78…”
Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines
Negri, D. R. M., Rossi, A., Blasi, M., Michelini, Z., Leone, P., Chiantore, M. V., Baroncelli, S., Perretta, G., Cimarelli, A., Klotman, M. E., et al. (2012) · Retrovirology · doi:10.1186/1742-4690-9-69 · Cited by 23
“both immunization and gene therapy purposes has been reported by several groups [1-11].”
BackgroundComplex Relationships between HIV-1 Integrase and Its Cellular Partners
Rozina, A., Anisenko, A. N., Kikhai, T. F., Silkina, M. O., & Gottikh, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012341 · Cited by 23
Xu, Z., Chen, F., Zhang, L., Lu, J., Xu, P., Liu, G., Xie, X., Mu, W., Wang, Y., & Liu, D. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-0067-0 · Cited by 20
Antiangiogenic Eye Gene Therapy
Corydon, T. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.064 · Cited by 21
“36–39 Regardless of surface proteins, subretinal injection of LV vectors primarily transduces RPE cells.”
Metadata
- Authors
- Apolonia, L., Waddington, S. N., Fernandes, C., Ward, N. J., Bouma, G., Blundell, M. P., Thrasher, A. J., Collins, M. K., & Philpott, N. J.
- Affiliations
- Great Ormond Street Hospital (GB)
- The Royal Free Hospital (GB)
- University College London (GB)
- Corresponding author
- Philpott, Nicola J
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2007-11
- Volume
- 15
- Issue
- 11
- Pages
- 1947-1954
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2075291405
- Semantic Scholar
- 850dac0bd2562c1b020bdefb90da8572837bc426
- Cited by
- 174
- References
- 44
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 8 · 2019: 6 · 2018: 4 · 2017: 8 · 2016: 15 · 2015: 12 · 2014: 12 · 2013: 10 · 2012: 12
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3263 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust
- Biotechnology and Biological Sciences Research Council
- Fundação para a Ciência e a Tecnologia
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- HIV-based vectors, insertional mutagenesis, myotubes, transgene expression, long terminal repeat, reverse transcription, in vivo gene delivery
- MeSH terms
- Animals, Cell Line, DNA, Viral, Genetic Vectors, Humans, Muscles, Mutation, Transduction, Genetic, Gene Expression, Lentivirus, Genome, Viral, Transgenes, Integrases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.